Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors.
作者： Cynthia X. Ma , Robert J. Crowder , Matthew J. Ellis
DOI: 10.1016/J.STEROIDS.2011.02.023
关键词:
摘要: Endocrine therapy has been the most effective treatment modality for hormone receptor positive breast cancer. However, its efficacy limited by either de novo or acquired resistance. Recent data indicates that activation of phosphatidylinositol 3-kinase (PI3K) signaling is associated with poor outcome luminal B subtype cancer and accompanied development endocrine Importantly, inhibition PI3K pathway in resistant cell lines reduces survival improves response to agents. Interestingly, mutations PIK3CA, alpha catalytic subunit class IA PI3K, which renders cells dependent on signaling, common genetic abnormality identified The synthetic lethality observed between estrogen deprivation (ER+) provides further scientific rational target both order improve ER+
elsevier.com
sci-hub.se 参考文章(32)
Robert J Crowder, Matthew J Ellis, Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway Breast Cancer Research. ,vol. 7, pp. 212- 214 ,(2005) , 10.1186/BCR1307
Maarit Bärlund, Outi Monni, Juha Kononen, Guido Sauter, Olli-P. Kallioniemi, Anne Kallioniemi, Joachim Torhorst, Robert Cornelison, Multiple genes at 17q23 undergo amplification and overexpression in breast cancer. Cancer Research. ,vol. 60, pp. 5340- 5344 ,(2000)
Deborah A Altomare, Joseph R Testa, Perturbations of the AKT signaling pathway in human cancer Oncogene. ,vol. 24, pp. 7455- 7464 ,(2005) , 10.1038/SJ.ONC.1209085
Tove Kirkegaard, Caroline J Witton, Liane M McGlynn, Sian M Tovey, Barbara Dunne, Alison Lyon, John MS Bartlett, AKT activation predicts outcome in breast cancer patients treated with tamoxifen. The Journal of Pathology. ,vol. 207, pp. 139- 146 ,(2005) , 10.1002/PATH.1829
Matthew J. Ellis, Li Lin, Robert Crowder, Yu Tao, Jeremy Hoog, Jacqueline Snider, Sherri Davies, Katherine DeSchryver, Dean B. Evans, Jutta Steinseifer, Raj Bandaru, WeiHua Liu, Humphrey Gardner, Vladimir Semiglazov, Mark Watson, Kelly Hunt, John Olson, José Baselga, Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Research and Treatment. ,vol. 119, pp. 379- 390 ,(2010) , 10.1007/S10549-009-0575-Y
Robert A. Campbell, Poornima Bhat-Nakshatri, Nikhil M. Patel, Demetra Constantinidou, Simak Ali, Harikrishna Nakshatri, Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α Journal of Biological Chemistry. ,vol. 276, pp. 9817- 9824 ,(2001) , 10.1074/JBC.M010840200
M S Kim, E G Jeong, N J Yoo, S H Lee, Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias British Journal of Cancer. ,vol. 98, pp. 1533- 1535 ,(2008) , 10.1038/SJ.BJC.6604212
L.A. deGraffenried, L. Fulcher, W.E. Friedrichs, V. Grünwald, R.B. Ray, M. Hidalgo, Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway Annals of Oncology. ,vol. 15, pp. 1510- 1516 ,(2004) , 10.1093/ANNONC/MDH388
John D. Carpten, Andrew L. Faber, Candice Horn, Gregory P. Donoho, Stephen L. Briggs, Christiane M. Robbins, Galen Hostetter, Sophie Boguslawski, Tracy Y. Moses, Stephanie Savage, Mark Uhlik, Aimin Lin, Jian Du, Yue-Wei Qian, Douglas J. Zeckner, Greg Tucker-Kellogg, Jeffrey Touchman, Ketan Patel, Spyro Mousses, Michael Bittner, Richard Schevitz, Mei-Huei T. Lai, Kerry L. Blanchard, James E. Thomas, A transforming mutation in the pleckstrin homology domain of AKT1 in cancer Nature. ,vol. 448, pp. 439- 444 ,(2007) , 10.1038/NATURE05933
Chad J. Creighton, Amy M. Hilger, Shalini Murthy, James M. Rae, Arul M. Chinnaiyan, Dorraya El-Ashry, Activation of Mitogen-Activated Protein Kinase in Estrogen Receptor α–Positive Breast Cancer Cells In vitro Induces an In vivo Molecular Phenotype of Estrogen Receptor α–Negative Human Breast Tumors Cancer Research. ,vol. 66, pp. 3903- 3911 ,(2006) , 10.1158/0008-5472.CAN-05-4363